Prognostication of Brain-Metastasized Patients Receiving Subsequent Systemic Therapy: A Single-Center Long-Term Follow-Up.

ABSTRACT:

Background

Survival of patients with brain metastases (BMs) is poor. It has become clear that targeted therapy has an effect on BMs and patient' prognosis. The question remains which patients benefit from additional systemic therapy. This assumption was evaluated in a large single-center cohort.

Methods

Patients consecutively planned to undergo local radiotherapy for their BMs in 2006-2017 were selected (n = 200). Prognosis, using CERENAL, disease-specific graded prognostic assessment (DS-GPA), and Radiation Therapy Oncology Group recursive partitioning analysis (RTOG RPA), was evaluated.

Results

Ninety-three (46.5%) patients received at least one additional line of systemic therapy subsequent to the diagnosis of their BMs. The median overall survival (OS) was

SUBMITTER: Vermassen T 

PROVIDER: S-EPMC11853900 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature